Literature DB >> 9591008

Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma.

M F Chen1, L B Jeng, W C Lee, T C Chen.   

Abstract

BACKGROUND: The purpose of our study was to report on the surgical outcomes of patients with hepatocellular carcinoma (HCC) with dual hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and to assess the differences in the surgical results between those patients and the patients with hepatitis B- or hepatitis C-related HCC.
METHODS: The operative outcomes of 13 patients with hepatitis B surface antigen (HBsAg)-positive and hepatitis C antibody (HCV Ab)-positive (the BC-HCC group) results, 57 patients with HBsAg-positive and HCV Ab-negative (the B-HCC group) results, and 34 patients with HBsAg-negative and HCV Ab-positive (the C-HCC group) results, who had undergone hepatic resection from 1991 to 1995, were compared.
RESULTS: The operative mortality rate within 1 month after operation for patients with BC-HCC was 7.7%. No statistically significant difference was found compared with the patients with B-HCC and C-HCC (5.3% and 5.9%, respectively). The postoperative course of patients with BC-HCC was complicated by liver failure, postoperative ascites, and wound infection in one patient each. Also, no statistically significant difference was found among the groups (23.1%, 22.8%, and 20.5% for patients with BC-HCC, B-HCC, and C-HCC, respectively). The overall 1-, 3-, and 5-year survival rates of patients with BC-HCC in this series were 75%, 50%, and 40%, respectively. The postoperative recurrence rate was 66.7%. No statistically significant differences were found between the various groups of the virus-related HCC on the overall survival rate and disease-free survival rate.
CONCLUSIONS: Hepatic resection for HCC in patients with dual HBV and HCV infections was associated with slightly higher operative morbidity and mortality rates, but there were no statistical differences compared with hepatitis B- or C-related HCC regarding the survival and recurrence rates.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591008     DOI: 10.1067/msy.1998.87237

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  14 in total

1.  Fatigue patterns and correlates in male liver cancer patients receiving transcatheter hepatic arterial chemoembolization.

Authors:  Shiow-Ching Shun; Yeur-Hur Lai; Ting-Ting Jing; Chii Jeng; Fa-Yau Lee; Li-Shia Hu; Sue-Yueh Cheng
Journal:  Support Care Cancer       Date:  2004-12-21       Impact factor: 3.603

2.  Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy.

Authors:  Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-04-08

3.  Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma.

Authors:  Yo Sasaki; Terumasa Yamada; Hideo Tanaka; Hiroaki Ohigashi; Hidetoshi Eguchi; Masahiko Yano; Osamu Ishikawa; Shingi Imaoka
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

4.  Influence of higher BMI for hepatitis B- and C-related hepatocellular carcinomas.

Authors:  Masakazu Hashimoto; Hirotaka Tashiro; Tsuyoshi Kobayashi; Shintaro Kuroda; Michinori Hamaoka; Hideki Ohdan
Journal:  Langenbecks Arch Surg       Date:  2017-05-22       Impact factor: 3.445

5.  Preoperative predictors of survival after resection of small hepatocellular carcinomas.

Authors:  Jeffrey D Wayne; Gregory Y Lauwers; Iwao Ikai; Dorota A Doherty; Jacques Belghiti; Yoshio Yamaoka; Jean-Marc Regimbeau; David M Nagorney; Kim-Anh Do; Lee M Ellis; Steven A Curley; Raphael E Pollock; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

6.  Hepatitis B or C virus serology as a prognostic factor in patients with hepatocellular carcinoma.

Authors:  S A Ahmad; M M Bilimoria; X Wang; F Izzo; P Delrio; P Marra; T P Baker; G A Porter; L M Ellis; J N Vauthey; S Dhamotharan; S A Curley
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

7.  Clinical experience of hepatic hemangioma undergoing hepatic resection.

Authors:  Hsiu-Pei Tsai; Long-Bin Jeng; Wei-Chen Lee; Miin-Fu Chen
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

8.  Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan.

Authors:  Nestor F Esnaola; Nadeem Mirza; Gregory Y Lauwers; Iwao Ikai; Jean-Marc Regimbeau; Jacques Belghiti; Yoshio Yamaoka; Steven A Curley; Lee M Ellis; David M Nagorney; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

9.  Clinical characteristics of hepatitis B core antibody-positive hepatocellular carcinoma.

Authors:  Takuya Nakai; Kenzo Koh; Takashi Kawabe; Osamu Shiraishi; Kiyotaka Okuno; Masayuki Yasutomi
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

10.  Surgical results in patients with hepatitis virus-related hepatocellular carcinoma in Taiwan.

Authors:  Miin-Fu Chen; Long-Bin Jeng; Wei-Chen Lee
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.